Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Japan ,Paris ,France General ,France ,Eva Schaefer Jansen ,Corentine Driancourt ,Felix Lauscher ,Sharon Chen ,Vesna Tosic ,Nathalie Pham ,Sally Bain ,Evans Dellon ,Priya Nanduri ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Drug Administration ,Dupilumab Development Program ,Nasdaq ,Exchange Commission ,Committee For Medicinal Products Human ,European Union ,University Of North Carolina School Medicine ,European Medicines Agency ,Euronext ,New England Journal ,Medicinal Products ,Human Use ,North Carolina School ,Dupixent Eosinophilic Esophagitis ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Digital Media ,Regeneron Pharmaceuticals ,Product Candidates ,Resume ,Careers ,Ress Release Positive Dupixent Dupilumab Phase 3 Results In Adults And Adolescents With Eosinophilic Esophagitis Published The New England Journal Of Medicine ,Iospace ,Advice ,